WorldCat Identities

Grávalos, Cristina

Overview
Works: 11 works in 11 publications in 2 languages and 19 library holdings
Roles: Other, Author, Contributor
Publication Timeline
.
Most widely held works by Cristina Grávalos
Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer by Antonio Jimeno( )

1 edition published in 2008 in English and held by 2 WorldCat member libraries worldwide

Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients by On behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR)( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer by Cristina Grávalos( )

1 edition published in 2011 in English and held by 2 WorldCat member libraries worldwide

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study by On behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)( )

1 edition published in 2015 in English and held by 2 WorldCat member libraries worldwide

A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients by on behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR)( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Algoritmo de decisión del tratamiento del cáncer gástrico by Cristina Grávalos( Book )

1 edition published in 2007 in Spanish and held by 1 WorldCat member library worldwide

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Abstract: Background: In the phase III RECOURSE trial, trifluridine/tipiracil (TAS-102) extended overall survival (OS) and progression-free survival (PFS) with an acceptable toxicity profile in patients with metastatic colorectal cancer refractory or intolerant to standard therapies. The present analysis investigated the efficacy and safety of trifluridine/tipiracil in RECOURSE subgroups. Methods: Primary and key secondary end-points were evaluated using a Cox proportional hazards model in prespecified subgroups, including geographical subregion (United States of America [USA], European Union [EU], Japan), age (<65 years, e"5 years) and v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homologue (KRAS) status (wild type, mutant). Safety and tolerability were reported with descriptive statistics. Results: Eight-hundred patients were enrolled: USA, n=99; EU, n=403; Japan, n=266. Patients aged e"5 years and those with mutant KRAS tumours comprised 44% and 51% of all patients in the subregions, respectively. Final OS analysis (including 89% of events, compared with 72% in the initial analysis) confirmed the survival benefit associated with trifluridine/tipiracil, with a hazard ratio (HR) of 0.69 (95% confidence interval [CI] 0.59-0.81; P=0.0001). Median OS in the three regions was 6.5-7.8 months in the trifluridine/tipiracil arm and 4.3-6.7 months in the placebo arm (USA: HR 0.56; 95% CI 0.34-0.94; P=0.0277; EU: HR 0.62; 95% CI 0.48-0.80; P=0.0002; Japan: HR 0.75; 95% CI 0.57-1.00; P=0.0470). Median PFS was 2.0-2.8 months for trifluridine/tipiracil and 1.7-1.8 months for placebo; HRs favoured trifluridine/tipiracil in all regions. Similar clinical benefits of trifluridine/tipiracil were observed in elderly patients and in those with mutant KRAS tumours. There were no marked differences among subregions in terms of safety and tolerability. Conclusions: Trifluridine/tipiracil was effective in all subgroups, regardless of age, geographical origin or KRAS status. This trial is registered with ClinicalTrials.gov:NCT01607957 . Highlights: Final OS analysis of the RECOURSE study by subregion (USA, EU, Japan) is described. Final survival benefit with trifluridine/tipiracil was HR 0.69 (95% CI 0.59-0.81; P=0.0001). Median OS and median PFS were 6.5-7.8 months and 2.0-2.8 months, respectively. Benefits were shown across subregions, for older patients and those with KRAS mutation. Trifluridine/tipiracil is effective in all subgroups regardless of age, geography or KRAS status
Experiencia clínica en síndrome de caquexia-anorexia by Cristina Grávalos( Book )

1 edition published in 2017 in Spanish and held by 1 WorldCat member library worldwide

 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.97 (from 0.88 for The subgro ... to 0.99 for Algoritmo ...)

Languages